Victory Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $78.8M | Sell |
126,343
-2,731
| -2% | -$1.86M | 0.04% | 392 |
|
|
2026
Q1 | $99.7M | Buy |
129,074
+17,110
| +15% | +$13.1M | 0.06% | 313 |
|
|
2025
Q4 | $86.4M | Buy |
111,964
+29,578
| +36% | +$20.1M | 0.05% | 347 |
|
|
2025
Q3 | $46.3M | Sell |
82,386
-87,892
| -52% | -$49.7M | 0.03% | 586 |
|
|
2025
Q2 | $91.3M | Buy |
170,278
+73,109
| +75% | +$40.8M | 0.06% | 331 |
|
|
2025
Q1 | $61.6M | Sell |
97,169
-42,722
| -31% | -$29.4M | 0.06% | 379 |
|
|
2024
Q4 | $99.6M | Buy |
139,891
+43,282
| +45% | +$36.3M | 0.1% | 238 |
|
|
2024
Q3 | $102M | Sell |
96,609
-2,273
| -2% | -$2.53M | 0.1% | 244 |
|
|
2024
Q2 | $104M | Sell |
98,882
-232
| -0.2% | -$225K | 0.1% | 230 |
|
|
2024
Q1 | $95.4M | Buy |
99,114
+6,223
| +7% | +$5.92M | 0.09% | 270 |
|
|
2023
Q4 | $81.6M | Buy |
92,891
+3,977
| +4% | +$3.28M | 0.09% | 299 |
|
|
2023
Q3 | $73.2M | Buy |
88,914
+11,370
| +15% | +$8.94M | 0.08% | 301 |
|
|
2023
Q2 | $55.7M | Sell |
77,544
-37,109
| -32% | -$28.6M | 0.06% | 399 |
|
|
2023
Q1 | $94.2M | Buy |
114,653
+24,362
| +27% | +$18.4M | 0.11% | 250 |
|
|
2022
Q4 | $65.1M | Sell |
90,291
-1,679
| -2% | -$1.24M | 0.08% | 354 |
|
|
2022
Q3 | $63.4M | Buy |
91,970
+14,603
| +19% | +$9.19M | 0.07% | 369 |
|
|
2022
Q2 | $45.7M | Sell |
77,367
-15,987
| -17% | -$10.4M | 0.05% | 506 |
|
|
2022
Q1 | $61.5M | Buy |
93,354
+2,281
| +3% | +$1.44M | 0.06% | 441 |
|
|
2021
Q4 | $57.5M | Buy |
91,073
+3,219
| +4% | +$1.98M | 0.05% | 511 |
|
|
2021
Q3 | $53.2M | Buy |
87,854
+3,780
| +4% | +$2.35M | 0.05% | 526 |
|
|
2021
Q2 | $47M | Buy |
84,074
+913
| +1% | +$463K | 0.05% | 587 |
|
|
2021
Q1 | $39.3M | Sell |
83,161
-4,063
| -5% | -$1.98M | 0.04% | 639 |
|
|
2020
Q4 | $42.1M | Buy |
87,224
+1,929
| +2% | +$1.04M | 0.05% | 574 |
|
|
2020
Q3 | $47.7M | Buy |
85,295
+3,188
| +4% | +$1.93M | 0.06% | 479 |
|
|
2020
Q2 | $51.2M | Buy |
82,107
+5,797
| +8% | +$3.29M | 0.07% | 418 |
|
|
2020
Q1 | $37.3M | Sell |
76,310
-7,917
| -9% | -$3.27M | 0.06% | 451 |
|
|
2019
Q4 | $31.6M | Buy |
84,227
+25,186
| +43% | +$8.47M | 0.04% | 651 |
|
|
2019
Q3 | $16.4M | Buy |
59,041
+51,100
| +643% | +$15.1M | 0.02% | 869 |
|
|
2019
Q2 | $2.49M | Buy |
7,941
+38
| +0.5% | +$12.7K | 0.01% | 1085 |
|
|
2019
Q1 | $3.25M | Sell |
7,903
-856
| -10% | -$352K | 0.01% | 968 |
|
|
2018
Q4 | $3.27M | Sell |
8,759
-26
| -0.3% | -$9.52K | 0.01% | 913 |
|
|
2018
Q3 | $3.55M | Buy |
8,785
+315
| +4% | +$120K | 0.01% | 970 |
|
|
2018
Q2 | $2.92M | Buy |
8,470
+835
| +11% | +$261K | 0.01% | 996 |
|
|
2018
Q1 | $2.63M | Buy |
7,635
+3,794
| +99% | +$1.32M | 0.01% | 999 |
|
|
2017
Q4 | $1.44M | Buy |
3,841
+229
| +6% | +$92.7K | ﹤0.01% | 1138 |
|
|
2017
Q3 | $1.61M | Sell |
3,612
-350
| -9% | -$167K | ﹤0.01% | 1070 |
|
|
2017
Q2 | $1.95M | Buy |
3,962
+395
| +11% | +$173K | ﹤0.01% | 962 |
|
|
2017
Q1 | $1.38M | Buy |
3,567
+694
| +24% | +$257K | ﹤0.01% | 1041 |
|
|
2016
Q4 | $1.05M | Buy |
2,873
+145
| +5% | +$55.1K | ﹤0.01% | 1110 |
|
|
2016
Q3 | $1.1M | Buy |
2,728
+376
| +16% | +$151K | ﹤0.01% | 992 |
|
|
2016
Q2 | $821K | Buy |
2,352
+45
| +2% | +$17.3K | ﹤0.01% | 866 |
|
|
2016
Q1 | $832K | Buy |
2,307
+235
| +11% | +$96.8K | ﹤0.01% | 872 |
|
|
2015
Q4 | $1.13M | Buy |
2,072
+1,067
| +106% | +$578K | ﹤0.01% | 760 |
|
|
2015
Q3 | $467K | Sell |
1,005
-62
| -6% | -$33.3K | ﹤0.01% | 1000 |
|
|
2015
Q2 | $541K | Buy |
+1,067
| New | +$521K | ﹤0.01% | 983 |
|
|
2013
Q4 | – | Sell |
-56
| Closed | -$17K | – | 1076 |
|
|
2013
Q3 | $17K | Buy |
+56
| New | +$14.7K | ﹤0.01% | 967 |
|
Other funds holding REGN
Victory Capital Management's REGN Position: Q2 2026 in Review
Victory Capital Management reduced its Regeneron Pharmaceuticals (REGN) stake by 2.1% in Q2 2026, selling an estimated $1.86M and leaving 126,343 shares worth $78.8M. The position accounts for 0.04% of the portfolio, ranked #392.
Victory Capital Management first reported a position in REGN in Q3 2013 and has held it in 46 quarters since. The position peaked at $104M in Q2 2024. 1,332 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Victory Capital Management held 126,343 shares of Regeneron Pharmaceuticals worth $78.8M as of Q2 2026.
- Victory Capital Management sold 2,731 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $1.86M.
- Regeneron Pharmaceuticals made up 0.04% of Victory Capital Management's portfolio in Q2 2026, its #392 holding.
- Victory Capital Management first reported a position in Regeneron Pharmaceuticals in Q3 2013 and has held it in 46 quarters since.
- Victory Capital Management's Regeneron Pharmaceuticals position peaked at $104M in Q2 2024.
- 1,332 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Victory Capital Management's 13F filing for Q2 2026, filed 7 Aug 2026.